This hypothesis is further supported by observations from our group and others that BCR-ABL-targeted therapies such as imatinib, dasatinib or nilotinib fail to eradicate CML LSC in vitro8, 9, 10, 42. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.